Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Asymmetric dimethylarginine levels are associated with augmentation index across naïve untreated patients with different hypertension phenotypes..
J Clin Hypertens (Greenwich). 20(4), 680-685.
(2018). Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas..
Cancer Genomics Proteomics. 15(5), 421-436.
(2018). Endothelial injury in rheumatoid arthritis: a crosstalk between dimethylarginines and systemic inflammation..
Arthritis Res Ther. 19(1), 32.
(2017).
(2017). Cumulative inflammation associates with asymmetric dimethylarginine in rheumatoid arthritis: a 6 year follow-up study..
Rheumatology (Oxford). 54(7), 1145-52.
(2015). Asymmetric dimethylarginine is not associated with subendocardial viability ratio in Rheumatoid Arthritis..
Int J Cardiol. 172(1), 285-6.
(2014).
(2014). Elevated asymmetric dimethylarginine is associated with oxidant stress aggravation in patients with early stage autosomal dominant polycystic kidney disease..
Kidney Blood Press Res. 38(1), 72-82.
(2013). Role of asymmetrical dimethylarginine in the progression of renal disease..
Nephrology (Carlton). 18(1), 11-21.
(2013). Biomarkers in pre-eclampsia: a novel approach to early detection of the disease..
J Obstet Gynaecol. 32(7), 609-16.
(2012). Correlation between asymmetric dimethylarginine maternal plasma levels and preeclampsia..
Clin Exp Obstet Gynecol. 38(2), 134-6.
(2011). Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome..
Hum Reprod Update. 17(6), 741-60.
(2011). Early detection of cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography: relationship with neurohormonal activation and endothelial dysfunction..
J Rheumatol. 37(5), 993-9.
(2010). Hormone therapy and asymmetrical dimethylarginine in postmenopausal women..
Hormones (Athens). 9(2), 127-35.
(2010).
(2010).
(2010). Decreased platelet nitric oxide contributes to increased circulating monocyte-platelet aggregates in hypertension..
Eur Heart J. 30(24), 3048-54.
(2009).